Amylyx Pharmaceuticals (AMLX) vs Tango Therapeutics (TNGX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Tango Therapeutics (TNGX) has outperformed Amylyx Pharmaceuticals (AMLX) over the past year, gaining 226.6% versus a gain of 101.8%. Tango Therapeutics is the larger company by market cap ($3.97 billion vs $3.54 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMLX | TNGX |
|---|---|---|
| Share price | $28.22 | $23.54 |
| Market cap | $3.54B | $3.97B |
| 1-day change | +3.73% | +4.30% |
| YTD return | +125.17% | +154.74% |
| 1-year return | +101.78% | +226.63% |
| 5-year return | — | +60.87% |
| EPS (TTM) | $-1.41 | $-0.85 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $62.38M |
| Revenue growth (YoY) | -100.00% | +48.29% |
| Net income (latest FY) | $-144.74M | $-101.59M |
| Operating margin | — | -178.39% |
| Net margin | — | -162.85% |
| 52-week high | $41.14 | $34.39 |
| 52-week low | $10.83 | $6.69 |
| Distance from 52-week high | -31.42% | -31.55% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +50.13% | +91.93% |
| Average volume | 2.35M | 2.65M |
| Shares outstanding | 125.51M | 168.61M |
| Employees | 136 | 137 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TNGX has outperformed AMLX by 124.8 percentage points over the past year.
- Tango Therapeutics grew revenue faster in its latest fiscal year (+48.29% vs -100.00%).
About Amylyx Pharmaceuticals
AMLX stock →Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism.
Health Care · Biotechnology: Pharmaceutical Preparations · 136 employees
About Tango Therapeutics
TNGX stock →Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 137 employees
AMLX vs TNGX FAQ
Which is bigger, Amylyx Pharmaceuticals or Tango Therapeutics?
Tango Therapeutics (TNGX) is larger, with a market capitalization of $3.97B compared with $3.54B for Amylyx Pharmaceuticals (AMLX).
Which stock has performed better over the past year, AMLX or TNGX?
TNGX returned +226.63% over the past 12 months, compared with +101.78% for AMLX (price return, excluding dividends). Past performance does not predict future results.
Are Amylyx Pharmaceuticals and Tango Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.